Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 13Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 6Lymphoma, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Immune System Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Proteostasis Deficiencies 1

Interventions

Melphalan 16Dexamethasone 15Bortezomib 11Peripheral Blood Stem Cell Transplantation 9Lenalidomide 9fludarabine phosphate 8Calcium Dobesilate 7pomalidomide 5fludarabine 5Busulfan 5carfilzomib 4Radiotherapy 4Prednisone 4Cyclophosphamide 4liposomal doxorubicin 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3Cyclosporine 3Arsenic Trioxide 3Alemtuzumab 3samarium Sm-153 lexidronam 2holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 2Whole-Body Irradiation 2Surveys and Questionnaires 2Pneumococcal Vaccines 2Granulocyte Colony-Stimulating Factor 2Bendamustine Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Plasma Cell × Bendamustine Hydrochloride × Clear all
NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Columbia University

Phase 1/2 Terminated
23 enrolled 13 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01002703 2011-08-12

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

University of Leipzig

Phase 1/2 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡